Biogen Inc.
BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for thā¦ read more
Healthcare
Drug ManufacturersāGeneral
33 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$138.60
Price+2.71%
$3.66
1Y
Price
Market Cap
$20.321b
Large
Price/Earnings 3y Avg5y Avg
13.3x
Premium
Premium
Financials Overview
Key metrics over the past few years+38.2%
EBITDA Margin+24.0%
Net Profit Margin+5.5%
Free Cash Flow MarginRevenue
$9.997b
+3.3%
1y CAGR-0.5%
3y CAGR-2.2%
5y CAGREarnings
$1.531b
-6.2%
1y CAGR-9.2%
3y CAGR+17.1%
5y CAGREPS
$10.49
-6.3%
1y CAGR-9.2%
3y CAGR+18.3%
5y CAGRBook Value
$17.634b
$28.330b
Assets$10.696b
Liabilities$6.595b
DebtDebt to Assets
23.3%
2.4x
Debt to EBITDAFree Cash Flow
$1.857b
-26.2%
1y CAGR+28.5%
3y CAGR+4.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company